InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
September 5, 2024
Predictive Oncology (NASDAQ: POAI) is announcing participation at the upcoming H.C. Wainwright 26th Annual Global Investment Conference to be held September 9-11 in New York. The company is scheduled to deliver a virtual presentation, which will be available on-demand starting Monday, September 9 at 7 a.m. ET. The Predictive Oncology management team will also host […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Reports on Study Confirming Long-Term Stability, Viability of Proprietary Tumor Specimen Biobank
August 27, 2024
Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, is reporting on a study that demonstrates the long-term stability and viability of the more than 150,000 cryopreserved patient tumor samples available within its proprietary biobank. According to the report, the study validates highly reproducible drug response data as well as enabling […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Q2 2024 Financial Results, Provides Business Update
August 14, 2024
Predictive Oncology (NASDAQ: POAI) today announced its financial and operating results for the second quarter ended June 30, 2024, and provided a corporate update. The company reported a net loss of approximately $3.2 million on total revenue of approximately $0.3 million for the quarter. In addition, it concluded Q2 2024 with $5.3 million of cash […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Expansion of Live-Cell Tumor Platform Applications
August 13, 2024
Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, has expanded the available applications for its platform to account for patient heterogeneity, derisk drug discovery and accelerated pipeline development. The company announced that its findings demonstrate real-world applications of POI’s AI platform to support biomarker discovery, clinical trial optimization and target […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Schedules Release of Q2 2024 Financial Results, Conference Call
August 7, 2024
Predictive Oncology (NASDAQ: POAI) is a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) to accelerate oncology drug discovery and enable drug development. The company expects to report its financial results for the second quarter of […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Enters into $1.2M Agreement for Exercise of Warrants
July 26, 2024
Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, has entered into a definitive agreement for the exercise of certain existing warrants. The agreement outlines the purchase of up to 958,117 shares of its common stock at a reduced exercise price of $1.32 per share; the shares were originally issued in […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Expands Its AI/ML Driven Platform to Include Novel Oncology Biomarker Discovery
July 25, 2024
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities to accelerate oncology drug discovery and enable drug development, is expanding its AI/ML driven drug discovery platform. According to the company, the expansion will include novel oncology biomarker discovery to be used to predict patient outcomes and drug response […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Unveils Novel Technology, Eyes Significant Partnership Opportunities
June 11, 2024
Predictive Oncology (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced the introduction of a new technology designed to express functional and stable G-Protein Coupled Receptors (“GPCRs”). GPCRs are cell surface membrane receptors believed to play a key role in tumorigenesis, with prior studies demonstrating involvement in cancer initiation, progression and metastasis. […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Launches Novel Technology to Accelerate Cancer Drug Discovery, Development
June 4, 2024
Predictive Oncology (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced the availability of its unique 3D cell culture model to advance cancer drug discovery and enable future drug development. More closely mimicking human tissue architecture than traditional 2D assays, organ-specific 3D cell cultures provide a more representative method for in vivo […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO to Participate at Upcoming BIO International Convention 2024
May 29, 2024
Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, will be spotlighted at next month’s BIO International Convention 2024. The conference is scheduled for June 3–6, 2024, in San Diego. According to the announcement, Predictive Oncology CEO Raymond Vennare will be presenting a company overview at the gathering. His presentation, titled […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Positive Results from Ovarian Cancer Study
May 28, 2024
Predictive Oncology (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that positive results from a retrospective study that the company recently completed in collaboration with UPMC Magee-Womens Hospital will be presented at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, which is being held May 31-June 4, 2024, in […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Q1 2024 Financial Results, Provides Business Update
May 15, 2024
Predictive Oncology (NASDAQ: POAI) is a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development. The company today announced financial and operating results for the quarter ended March 31, 2024, and provided a […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Schedules Release of Q1 2024 Financial Results, Conference Call
May 10, 2024
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities to accelerate oncology drug discovery and enable drug development, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Wednesday, May 15, 2024, before the markets open. In addition, on that […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Partners with FluGen to Develop First-of-Its-Kind Intranasal Flu Vaccine for Global Distribution
May 1, 2024
Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, is partnering with FluGen to bring a first-of-its-kind intranasal flu vaccine to market. According to the announcement, the partnership is part of a $6.2 million phase 2B grant awarded by the United States Department of Defense (“DoD”). The collaboration involves members of […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Engages IBN for Corporate Communications Expertise
April 25, 2024
Nutriband (NASDAQ: NTRB, NTRBW), a pharmaceutical company with a special focus on transdermal technologies, today announced that it has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. According to the announcement, Nutriband’s AVERSA(TM) technology can be incorporated into any transdermal patch and […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Abstract to Be Presented Next Month at ASCO Annual Meeting
April 25, 2024
Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, announced that its abstract has been accepted for presentation at the upcoming American Society of Clinical Oncology (“ASCO”) annual meeting. This year’s meeting is slated for May 31–June 4, 2024, in Chicago. According to the company, the abstract contains data and results […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Year-End 2023 Financial Report, Business Update
April 1, 2024
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial-intelligence (“AI”) and machine-learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, is reporting on its financial and operating results for the year ended Dec. 31, 2023; the company also released a corporate […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO to Present at Three Upcoming Events
February 22, 2024
Predictive Oncology (NASDAQ: POAI), a leader in artificial intelligence (“AI”)-driven drug discovery and biologics, will be represented at three upcoming conferences: the BIO CEO & Investor Conference, the 2024 NeauxCancer Oncology Conference and H.C. Wainwright’s first Artificial Intelligence Based Drug Discovery & Development virtual conference. According to the announcement, POAI CEO Raymond F. Vennare will […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Participation in January Conferences
January 2, 2024
Predictive Oncology (NASDAQ: POAI), a leader in artificial intelligence (“AI”)-driven drug discovery and biologics, will be attending three upcoming conferences: Biotech Showcase, LifeSco Partners Corporate Access Event and BIO Partnering@JPM Week 2024. All three events are slated for Jan. 8–10, 2024, in San Francisco. According to the announcement, POAI CEO Raymond F. Vennare will be […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Q3 2023 Financial Results, Business Update
November 14, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence (“AI”) and machine-learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, is reported its financial and operating results for the three- and nine-month periods ending Sept. 30, 2023. Highlights of the […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), UPMC Magee-Womens Hospital Complete Ovarian Cancer Study
November 8, 2023
Predictive Oncology (NASDAQ: POAI), a leader in artificial intelligence (“AI”)-driven drug discovery and biologics, has completed a multiyear study through a partnership with UPMC Magee-Womens Hospital. The study was focused on evaluating the use of AI in building multiomic machine learning (“ML”) models and then testing the models to determine if they could learn associations between […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Schedules Release of Q3 Results, Corporate Update Call
November 7, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development, is planning to release its financial results for Q3 2023. The company announced it […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Q2 2023 Financial Results, Corporate Update
August 11, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development, is reporting on its Q2 2023 performance. The company reported financial and operating results […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Plans to Release Q2 2023 Financial Results, Host Earnings Call
August 3, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development will report its financial results next week. The company announced that it will release […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Moves Corporate HQ to Pittsburgh
July 18, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence (“AI”) and machine-learning capabilities, its extensive biorepository of tumor samples, and its Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development, is moving to Pittsburg. The company announced that it has relocated […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Finance Veteran as Newest Business Advisory Board Member
June 27, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence (“AI”) and machine-learning capabilities, its extensive biorepository of tumor samples, and its Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development, has appointed a new member to its business advisory board. The […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Advisory Board Appointment of Dr. Bernard A. Harris, Jr.
June 20, 2023
Predictive Oncology (NASDAQ: POAI) is a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development. The company today announced the appointment of Dr. Bernard A. Harris, Jr. […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) to Present Groundbreaking PEDAL Approach at 2023 BIO International Convention
May 23, 2023
Predictive Oncology (NASDAQ: POAI) today announced that its Chief Business Officer Pamela Bush, Ph.D., MBA will present at the upcoming 2023 BIO International Convention, in Boston, Massachusetts, on June 5, 2023. Dr. Bush, beginning at 2:45 p.m. ET in presentation room 103, will discuss the importance of addressing patient heterogeneity in drug discovery and the […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Q1 2023 Financial Report, Business Update
May 16, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence (“AI”) and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, is reporting on its financial and operating results for the three months ended March 31, 2023. According to the report, […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) to Report First Quarter 2023 Results, Host Conference Call and Webcast
May 8, 2023
Predictive Oncology (NASDAQ: POAI) is a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development. The company today announced that it will report its financial results for […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Appoints Seasoned Veteran as New Board Member
May 3, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, announced the appointment of a new board member. healthcare commercial and business development veteran Veena Rao, PhD., MBA, will be serving […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Reverse Stock Split Approved, Effective April 24
April 21, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, has announced a reverse stock split of its common stock. According to the announcement, the stock split will be effective Monday, […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Special Meeting of Stockholders Rescheduled after ‘Lack of Required Quorum’
April 18, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, has adjourned its Special Meeting of stockholders. The company held the meeting on April 17, 2023, at 3 p.m., and then […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Oncology Translational Research Leader to Scientific Advisory Board
April 4, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, has appointed Christoph Reinhard, PhD, MBA, to its Scientific Advisory Board. Reinhard will join other board members who are thought leaders […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Integra Therapeutics Collaborate to Advance Gene Therapy
March 30, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company on the leading edge of oncology drug discovery and development, today announced that it is partnering with Integra Therapeutics, a company focused on engineering the next generation of gene writing tools to cure diseases. According to the announcement, the collaboration was created to pursue a novel method to […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Collaborates to Leverage AI for New Cancer Drugs, Announces 2022 Results
March 22, 2023
Predictive Oncology’s (NASDAQ: POAI) chief business officer Pamela Bush and Dom Pollard, business development manager at Cancer Research Horizons, joined Proactive’s Natalie Stoberman to discuss their partnership for new cancer drug development. According to the announcement, “The collaboration will utilize Predictive Oncology’s PEDAL technology [an artificial intelligence (‘AI’) and machine learning platform] to evaluate Cancer […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Key Partnership, Declares Dividend
March 17, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, is collaborating with Cancer Research Horizons in the development of oncology drugs utilizing its proprietary PEDAL(TM) platform. Cancer Research Horizons is the […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Engages with Leading IR Consultant to Implement Comprehensive IR Effort
March 14, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, has announced a new partnership. The company is working with LifeSci Advisors to implement a comprehensive IR program. The company anticipates […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Updates Shareholders, Provides Company Overview and Plans for Future
March 9, 2023
Predictive Oncology (NASDAQ: POAI) CEO Raymond Vennare has issued a letter to shareholders, providing an overview of the company and a look at the significant progress the company has made in respect to validating its commercial platform and publishing its proof of concept. In the letter, Vennare noted that Predictive Oncology is now in a […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO Talks New Cvergenx Partnership During Proactive Interview
March 1, 2023
Predictive Oncology (NASDAQ: POAI) CEO Raymond Vennare was a featured guest during the latest interview released by Proactive US. Vennare joined Cvergenx CEO Javier Torres-Roca to talk about the recent announcement that the two companies have joined forces to create a new genomic-based artificial intelligence (“AI”) radiation therapy. Host Natalie Stoberman facilitated the discussion, in […]